8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 11, 2026·SEC
Material company update
Jan 27, 2026·SEC
Outset Medical, Inc.(OM)Earnings, Financials & Key Ratios
OM•NASDAQ
$4.68
$87M mkt cap·Price updated May 7, 2026
AboutOutset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.Show more
- Revenue$119M+5.1%
- EBITDA-$62M+42.1%
- Net Income-$82M+36.2%
- EPS (Diluted)-5.37+85.5%
- Gross Margin39.13%+15.4%
- EBITDA Margin-52.21%+44.9%
- Operating Margin-55.84%+44.0%
- Net Margin-68.34%+39.3%
- ROE-106.2%+37.9%
- ROIC-33.23%+42.3%
- Debt/Equity0.82-89.1%
- Interest Coverage-4.78-5.9%
OM Key Insights
Outset Medical, Inc. (OM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 19.1%
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OM Price & Volume
Outset Medical, Inc. (OM) stock price & volume — 10-year historical chart
Loading chart...
OM Growth Metrics
Outset Medical, Inc. (OM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years19.06%
3 Years1.17%
TTM2.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM34.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.41%
Return on Capital
10 Years-45.48%
5 Years-41.48%
3 Years-43.84%
Last Year-29.18%
OM Peer Comparison
Outset Medical, Inc. (OM) competitors in Renal, dialysis, and blood purification — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 DVA | 12.6B | 196.28 | 20.64 | 6.46% | 5.65% | 59.11% | 12.99 | |
 FMS | 11.92B | 21.65 | 10.96 | 1.51% | 4.89% | 6.68% | 0.76 | |
 HCAT | 112.89M | 1.59 | -0.62 | 1.48% | -57.2% | -54.67% | 0.08 | |
 BDX | 55.53B | 153.26 | 26.29 | 8.23% | 5.33% | 4.54% | 0.76 | |
 BAX | 9.04B | 17.51 | -10.01 | 5.72% | -9.7% | -16.5% | 1.64 | |
 RMD | 30.15B | 206.96 | 21.76 | 9.84% | 27.44% | 24.41% | 0.14 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 MMSI | 3.72B | 62.33 | 29.26 | 11.66% | 9.03% | 8.95% | 0.57 |
Compare OM vs Peers
Outset Medical, Inc. (OM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OM Income Statement
Outset Medical, Inc. (OM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.01M | 15.08M | 49.94M | 102.6M | 115.38M | 130.38M | 113.69M | 119.48M | 117.59M |
| Revenue Growth % | - | 651.27% | 231.18% | 105.47% | 12.45% | 13% | -12.8% | 5.09% | 2.01% |
| Cost of Goods Sold | 8.12M | 32.88M | 62.97M | 94.99M | 97.54M | 101.38M | 75.13M | 72.72M | 69.8M |
| COGS % of Revenue | 404.68% | 218.07% | 126.11% | 92.58% | 84.54% | 77.76% | 66.08% | 60.87% | - |
| Gross Profit | -6.12M▲ 0% | -17.8M▼ 191.1% | -13.04M▲ 26.8% | 7.61M▲ 158.4% | 17.83M▲ 134.4% | 29M▲ 62.6% | 38.56M▲ 33.0% | 46.75M▲ 21.2% | 47.78M▲ 0% |
| Gross Margin % | -304.68% | -118.07% | -26.11% | 7.42% | 15.46% | 22.24% | 33.92% | 39.13% | 40.64% |
| Gross Profit Growth % | - | -191.12% | 26.77% | 158.36% | 134.4% | 62.62% | 32.98% | 21.24% | - |
| Operating Expenses | 40.45M | 52.51M | 104.43M | 138.13M | 178.85M | 198.77M | 151.94M | 113.46M | 114.72M |
| OpEx % of Revenue | 2015.35% | 348.22% | 209.13% | 134.62% | 155.02% | 152.46% | 133.64% | 94.96% | - |
| Selling, General & Admin | 17.53M | 29.18M | 75.58M | 101.39M | 130M | 141.46M | 113.54M | 92.22M | 93.67M |
| SG&A % of Revenue | 873.54% | 193.51% | 151.36% | 98.81% | 112.67% | 108.5% | 99.87% | 77.19% | - |
| Research & Development | 22.92M | 23.33M | 28.85M | 36.74M | 48.85M | 57.31M | 38.4M | 21.23M | 21.34M |
| R&D % of Revenue | 1141.8% | 154.71% | 57.78% | 35.81% | 42.34% | 43.96% | 33.77% | 17.77% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -284K |
| Operating Income | -46.56M▲ 0% | -70.31M▼ 51.0% | -117.47M▼ 67.1% | -130.52M▼ 11.1% | -161.02M▼ 23.4% | -169.77M▼ 5.4% | -113.38M▲ 33.2% | -66.71M▲ 41.2% | -66.94M▲ 0% |
| Operating Margin % | -2320.03% | -466.29% | -235.24% | -127.21% | -139.56% | -130.22% | -99.72% | -55.84% | -56.93% |
| Operating Income Growth % | - | -50.99% | -67.08% | -11.11% | -23.37% | -5.43% | 33.22% | 41.16% | - |
| EBITDA | -45.07M | -68.37M | -113.71M | -125.36M | -154.74M | -163.96M | -107.65M | -62.37M | -64.58M |
| EBITDA Margin % | -2245.59% | -453.46% | -227.72% | -122.18% | -134.12% | -125.76% | -94.69% | -52.21% | -54.92% |
| EBITDA Growth % | - | -51.71% | -66.31% | -10.24% | -23.44% | -5.96% | 34.35% | 42.06% | 25.37% |
| D&A (Non-Cash Add-back) | 1.49M | 1.94M | 3.75M | 5.16M | 6.28M | 5.81M | 5.73M | 4.34M | 2.36M |
| EBIT | -45.12M | -64.02M | -118.6M | -130.02M | -159.09M | -159.6M | -107.82M | -66.71M | -48.17M |
| Net Interest Income | -2.93M | -1.77M | -2.37M | -1.22M | -275K | -2.5M | -14.11M | -6.54M | -4.96M |
| Interest Income | 1.71M | 2.48M | 526K | 498K | 3.29M | 10.17M | 9.76M | 7.41M | 5.43M |
| Interest Expense | 4.64M | 4.26M | 2.89M | 1.72M | 3.57M | 12.68M | 23.87M | 13.95M | 7.02M |
| Other Income/Expense | -3.19M | 2.03M | -4.03M | -1.22M | -1.64M | -2.5M | -14.11M | -14.22M | -7.09M |
| Pretax Income | -49.76M▲ 0% | -68.28M▼ 37.2% | -121.49M▼ 77.9% | -131.74M▼ 8.4% | -162.66M▼ 23.5% | -172.27M▼ 5.9% | -127.48M▲ 26.0% | -80.94M▲ 36.5% | -74.03M▲ 0% |
| Pretax Margin % | -2479.07% | -452.84% | -243.3% | -128.4% | -140.98% | -132.14% | -112.13% | -67.74% | -62.96% |
| Income Tax | 25K | 20K | 0 | 199K | 295K | 523K | 491K | 718K | 820K |
| Effective Tax Rate % | -0.05% | -0.03% | 0% | -0.15% | -0.18% | -0.3% | -0.39% | -0.89% | -1.11% |
| Net Income | -49.78M▲ 0% | -68.3M▼ 37.2% | -121.49M▼ 77.9% | -131.94M▼ 8.6% | -162.96M▼ 23.5% | -172.8M▼ 6.0% | -127.98M▲ 25.9% | -81.65M▲ 36.2% | -74.85M▲ 0% |
| Net Margin % | -2480.32% | -452.97% | -243.3% | -128.59% | -141.24% | -132.54% | -112.57% | -68.34% | -63.65% |
| Net Income Growth % | - | -37.2% | -77.88% | -8.6% | -23.51% | -6.04% | 25.94% | 36.2% | 34.24% |
| Net Income (Continuing) | -49.78M | -68.3M | -121.49M | -131.94M | -162.96M | -172.8M | -127.98M | -81.65M | -74.85M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.65▲ 0% | -34.06▼ 1964.2% | -2.83▲ 91.7% | -43.41▼ 1433.9% | -50.75▼ 16.9% | -52.27▼ 3.0% | -36.95▲ 29.3% | -5.37▲ 85.5% | -4.07▲ 0% |
| EPS Growth % | - | -1964.24% | 91.69% | -1433.92% | -16.91% | -3% | 29.31% | 85.47% | 87.41% |
| EPS (Basic) | -1.65 | -1.61 | -2.83 | -43.41 | -50.75 | -52.27 | -36.95 | -5.37 | - |
| Diluted Shares Outstanding | 2.01M | 2.01M | 2.85M | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M | 18.37M |
| Basic Shares Outstanding | 2.01M | 2.01M | 2.85M | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M | 18.37M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
OM Balance Sheet
Outset Medical, Inc. (OM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 147.65M | 79.65M | 345.91M | 409.8M | 373.64M | 291.22M | 258.22M | 250.88M | 236.71M |
| Cash & Short-Term Investments | 142.78M | 70.08M | 314.87M | 339.49M | 287.5M | 203.32M | 158.69M | 168.95M | 156.71M |
| Cash Only | 33.26M | 36.93M | 294.97M | 182.35M | 73.22M | 68.51M | 124.01M | 35.01M | 30.56M |
| Short-Term Investments | 109.52M | 33.15M | 19.9M | 157.14M | 214.28M | 134.81M | 34.67M | 133.94M | 126.14M |
| Accounts Receivable | 1.09M | 3.91M | 6.47M | 25.6M | 28.07M | 32.98M | 35.62M | 28.33M | 25.32M |
| Days Sales Outstanding | 197.87 | 94.75 | 47.28 | 91.07 | 88.8 | 92.33 | 114.36 | 86.55 | 94.29 |
| Inventory | 3.02M | 4.6M | 18.38M | 39.19M | 51.48M | 49.22M | 59.39M | 47.61M | 49.65M |
| Days Inventory Outstanding | 135.81 | 51.02 | 106.56 | 150.56 | 192.62 | 177.2 | 288.54 | 238.96 | 259.87 |
| Other Current Assets | 0 | 0 | 6.19M | 0 | 6.6M | 5.7M | 4.53M | 6M | 5.03M |
| Total Non-Current Assets | 3.48M | 8.72M | 57.92M | 53.66M | 26.47M | 22.58M | 17.57M | 13.61M | 12.74M |
| Property, Plant & Equipment | 2.93M | 7.89M | 23.25M | 20.2M | 21.99M | 18.65M | 12.07M | 9.47M | 8.56M |
| Fixed Asset Turnover | 0.69x | 1.91x | 2.15x | 5.08x | 5.25x | 6.99x | 9.42x | 12.62x | 13.29x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 151K | 743K | 0 | 33.31M | 3.31M | 0 | 0 | 3.83M | 7.16M |
| Other Non-Current Assets | 407K | 82K | 34.67M | 156K | 1.17M | 3.93M | 5.5M | 317K | 8.93M |
| Total Assets | 151.13M▲ 0% | 88.37M▼ 41.5% | 403.83M▲ 357.0% | 463.46M▲ 14.8% | 400.12M▼ 13.7% | 313.8M▼ 21.6% | 275.8M▼ 12.1% | 264.5M▼ 4.1% | 249.45M▲ 0% |
| Asset Turnover | 0.01x | 0.17x | 0.12x | 0.22x | 0.29x | 0.42x | 0.41x | 0.45x | 0.44x |
| Asset Growth % | - | -41.53% | 357% | 14.77% | -13.67% | -21.57% | -12.11% | -4.1% | -34.8% |
| Total Current Liabilities | 10.21M | 24.91M | 36.69M | 51.7M | 51.95M | 55.32M | 45.38M | 37.63M | 37.61M |
| Accounts Payable | 3.37M | 4.96M | 4.95M | 1.76M | 603K | 5.83M | 3.86M | 554K | 1.44M |
| Days Payables Outstanding | 151.58 | 55.06 | 28.68 | 6.77 | 2.26 | 20.98 | 18.76 | 2.78 | 6.75 |
| Short-Term Debt | 10K | 7.5M | 0 | 0 | 0 | 0 | 1.8M | 1.74M | 1.82M |
| Deferred Revenue (Current) | 269K | 883K | 3.2M | 6.34M | 8.66M | 11.73M | 12.75M | 13.79M | 55.34M |
| Other Current Liabilities | 2.23M | 4.61M | 10.82M | 17.49M | 19.85M | 24.77M | 25.16M | 10.81M | 23.14M |
| Current Ratio | 14.46x | 3.20x | 9.43x | 7.93x | 7.19x | 5.26x | 5.69x | 6.67x | 6.67x |
| Quick Ratio | 14.16x | 3.01x | 8.93x | 7.17x | 6.20x | 4.37x | 4.38x | 5.40x | 5.40x |
| Cash Conversion Cycle | 182.09 | 90.71 | 125.16 | 234.86 | 279.17 | 248.55 | 384.13 | 322.72 | 347.41 |
| Total Non-Current Liabilities | 428.87M | 435.64M | 38.53M | 37.69M | 102.18M | 135.59M | 203.6M | 99.91M | 100.16M |
| Long-Term Debt | 28.35M | 21.56M | 29.67M | 29.76M | 96.34M | 130.11M | 197.38M | 99.51M | 2.86M |
| Capital Lease Obligations | 9K | 0 | 8.04M | 6.89M | 5.58M | 4.48M | 2.68M | 3.27M | 6.22M |
| Deferred Tax Liabilities | -9K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 400.5M | 413.95M | 240K | 721K | 113K | 896K | 2.69M | -3.27M | 92.79M |
| Total Liabilities | 439.08M | 460.55M | 75.22M | 89.38M | 154.13M | 190.91M | 248.98M | 137.54M | 137.77M |
| Total Debt | 28.86M | 29.06M | 38.6M | 37.81M | 103.23M | 136.19M | 201.86M | 104.52M | 4.68M |
| Net Debt | -4.4M | -7.87M | -256.37M | -144.54M | 30.01M | 67.68M | 77.84M | 69.51M | -25.89M |
| Debt / Equity | - | - | 0.12x | 0.10x | 0.42x | 1.11x | 7.53x | 0.82x | 0.82x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.07x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.40x |
| Interest Coverage | -9.73x | -15.04x | -41.02x | -75.81x | -44.61x | -12.59x | -4.52x | -4.78x | -6.86x |
| Total Equity | -287.95M▲ 0% | -372.19M▼ 29.3% | 328.61M▲ 188.3% | 374.08M▲ 13.8% | 245.99M▼ 34.2% | 122.89M▼ 50.0% | 26.82M▼ 78.2% | 126.95M▲ 373.4% | 111.69M▲ 0% |
| Equity Growth % | - | -29.25% | 188.29% | 13.84% | -34.24% | -50.04% | -78.18% | 373.37% | 662.45% |
| Book Value per Share | -143.58 | -185.58 | 115.38 | 123.08 | 76.61 | 37.17 | 7.74 | 8.35 | 6.08 |
| Total Shareholders' Equity | -287.95M | -372.19M | 328.61M | 374.08M | 245.99M | 122.89M | 26.82M | 126.95M | 111.69M |
| Common Stock | 1K | 1K | 43K | 47K | 48K | 50K | 53K | 18K | 18K |
| Retained Earnings | -287.89M | -372.57M | -494.06M | -625.99M | -788.95M | -961.75M | -1.09B | -1.17B | -1.19B |
| Treasury Stock | 0 | -356K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -60K | 22K | 1K | -184K | -564K | 68K | 42K | 172K | -73K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OM Cash Flow Statement
Outset Medical, Inc. (OM) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -46.44M | -70.29M | -99.02M | -130.26M | -145.73M | -131.37M | -116.3M | -46.33M | -46.33M |
| Operating CF Margin % | -2314% | -466.19% | -198.29% | -126.96% | -126.31% | -100.76% | -102.3% | -38.78% | - |
| Operating CF Growth % | - | -51.35% | -40.86% | -31.56% | -11.87% | 9.85% | 11.47% | 60.17% | 247.01% |
| Net Income | -49.78M | -68.3M | -121.49M | -131.94M | -162.96M | -172.8M | -127.98M | 0 | -74.85M |
| Depreciation & Amortization | 1.07M | 1.94M | 3.16M | 5.16M | 5.17M | 5.81M | 5.73M | 0 | 1.73M |
| Stock-Based Compensation | 788K | 883K | 21.44M | 17.45M | 27.2M | 38.63M | 29.36M | 0 | 12.64M |
| Deferred Taxes | -75K | -4.11M | 2.49M | 3.08M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.77M | 893K | 1.24M | 1.59M | 6M | -2.25M | 2.28M | -48.53M | 6.06M |
| Working Capital Changes | -217K | -1.6M | -5.85M | -25.6M | -21.14M | -773K | -25.69M | 2.2M | 14.77M |
| Change in Receivables | -552K | -2.89M | -2.57M | -19.14M | -2.51M | -5.09M | -5.01M | 3.77M | 5.24M |
| Change in Inventory | -2.21M | -5.02M | -16.29M | -22.04M | -14.73M | 1.65M | -10.86M | 11.79M | 8.1M |
| Change in Payables | 2.67M | 802K | 737K | -3.07M | -1.28M | 5.31M | -1.95M | -3.29M | -521K |
| Cash from Investing | -68.78M | 74.3M | 3.95M | -142.51M | -66.3M | 83.03M | 103.94M | -97.68M | -11.71M |
| Capital Expenditures | -1.77M | -3.29M | -9.11M | -3.11M | -8.32M | -3.44M | -912K | -798K | -675K |
| CapEx % of Revenue | 87.99% | 21.84% | 18.24% | 3.03% | 7.22% | 2.64% | 0.8% | 0.67% | - |
| Acquisitions | 0 | -77.59M | 31K | 139.4M | 57.97M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -67.01M | 77.59M | 0 | -139.4M | -57.97M | 0 | 0 | 0 | 7.9M |
| Cash from Financing | 134.87M | 249K | 385.68M | 160.15M | 72.9M | 43.65M | 67.87M | 55.5M | 348K |
| Debt Issued (Net) | -9K | -9K | -1.36M | 0 | 64.86M | 33.23M | 66.52M | -106.68M | 0 |
| Equity Issued (Net) | 134.57M | 0 | 0 | 149.09M | 8.04M | 10.43M | 2.28M | 162.19M | -153K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 314K | 258K | 387.05M | 11.06M | 0 | 0 | -938K | 0 | 501K |
| Net Change in Cash | 19.65M▲ 0% | 4.25M▼ 78.4% | 290.61M▲ 6731.5% | -112.62M▼ 138.8% | -139.13M▼ 23.5% | -4.7M▲ 96.6% | 55.51M▲ 1282.2% | -88.51M▼ 259.5% | -44.87M▲ 0% |
| Free Cash Flow | -48.21M▲ 0% | -73.58M▼ 52.6% | -108.12M▼ 46.9% | -133.37M▼ 23.4% | -154.05M▼ 15.5% | -134.81M▲ 12.5% | -117.22M▲ 13.1% | -47.13M▲ 59.8% | -34.18M▲ 0% |
| FCF Margin % | -2401.99% | -488.03% | -216.53% | -129.99% | -133.52% | -103.4% | -103.1% | -39.44% | -29.07% |
| FCF Growth % | - | -52.64% | -46.94% | -23.35% | -15.51% | 12.49% | 13.05% | 59.8% | 64.66% |
| FCF per Share | -24.04 | -36.69 | -37.96 | -43.88 | -47.98 | -40.78 | -33.84 | -3.10 | -3.10 |
| FCF Conversion (FCF/Net Income) | 0.93x | 1.03x | 0.81x | 0.99x | 0.89x | 0.76x | 0.91x | 0.57x | 0.46x |
| Interest Paid | 3.29M | 3.35M | 3.27M | 1.15M | 3.19M | 10.85M | 20.68M | 15.63M | 8.27M |
| Taxes Paid | 9K | 35K | 19K | 83K | 385K | 491K | 593K | 447K | 339K |
OM Key Ratios
Outset Medical, Inc. (OM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -36.97% | -37.55% | -52.56% | -93.69% | -170.97% | -106.2% | -55.88% |
| Return on Invested Capital (ROIC) | - | - | -64.88% | -47.78% | -54.58% | -57.6% | -33.23% | -33.23% |
| Gross Margin | -118.07% | -26.11% | 7.42% | 15.46% | 22.24% | 33.92% | 39.13% | 40.64% |
| Net Margin | -452.97% | -243.3% | -128.59% | -141.24% | -132.54% | -112.57% | -68.34% | -63.65% |
| Debt / Equity | - | 0.12x | 0.10x | 0.42x | 1.11x | 7.53x | 0.82x | 0.82x |
| Interest Coverage | -15.04x | -41.02x | -75.81x | -44.61x | -12.59x | -4.52x | -4.78x | -6.86x |
| FCF Conversion | 1.03x | 0.81x | 0.99x | 0.89x | 0.76x | 0.91x | 0.57x | 0.46x |
| Revenue Growth | 651.27% | 231.18% | 105.47% | 12.45% | 13% | -12.8% | 5.09% | 2.01% |
OM SEC Filings & Documents
Outset Medical, Inc. (OM) SEC filings — annual & quarterly reports (10-K, 10-Q)
OM Frequently Asked Questions
Outset Medical, Inc. (OM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Outset Medical, Inc. (OM) reported $117.6M in revenue for fiscal year 2025. This represents a 5759% increase from $2.0M in 2018.
Outset Medical, Inc. (OM) grew revenue by 5.1% over the past year. This is steady growth.
Outset Medical, Inc. (OM) reported a net loss of $74.8M for fiscal year 2025.
Dividend & Returns
Outset Medical, Inc. (OM) has a return on equity (ROE) of -106.2%. Negative ROE indicates the company is unprofitable.
Outset Medical, Inc. (OM) had negative free cash flow of $34.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More OM
Outset Medical, Inc. (OM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates